(Q57696013)

1

0 references

Anar Gulamhussein

2

0 references

E.Jenny Heathcote

3

0 references

Les Lilly

4

0 references

Morris Sherman

5

0 references

Gary Naglie

The American Journal of Gastroenterology

6

0 references

language of work or name

English

0 references

publication date

March 2003

0 references

published in

0 references

volume

98

0 references

page(s)

630-638

0 references

issue

3

0 references

cites work

Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07332.X

Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07332.X

The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07332.X

Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07332.X

Cost effectiveness analysis of different strategies of management of chronic hepatitis C infection in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07332.X

A model of the health and economic impact of posttransfusion hepatitis C: application to cost-effectiveness analysis of further expansion of HCV screening protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07332.X

Comorbidities and quality of life in patients with interferon-refractory chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07332.X

Therapy of hepatitis C: cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07332.X

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07332.X

Construction of the Patient-Oriented Prostate Utility Scale (PORPUS): a multiattribute health state classification system for prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07332.X

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07332.X

Comparison of the EQ-5D and SF-12 health surveys in a general population survey in Alberta, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07332.X

Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07332.X

Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07332.X

Hepatitis C virus infection: quality of life and side effects of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07332.X

Assessment of utilities and health-related quality of life in patients with chronic liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07332.X

Comorbid Illness is Associated with Survival and Length of Hospital Stay in Patients with Chronic Disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07332.X